Compare Baker Hughes Co (BKR) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Johnson & Johnson — how do they compare? Baker Hughes Co trades at $64.64 (market cap $64.34B), while Johnson & Johnson trades at $257.65 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 9.7× Baker Hughes Co's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| BKR | JNJ | |
|---|---|---|
Market Cap | $64.34B | $626.09B |
Sector | Energy | Health |
52-Week High | $69.67 | $267.24 |
52-Week Low | $42.51 | $172.78 |
Enterprise Value | $64.86B | $654.37B |
Dividend Yield | 1.42% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.07, up 4.09% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.64 exceeding expectations. Recent contract wins in subsea systems and LNG technology, along with the Chart Industries acquisition, position the company for growth despite modest oil & gas spending headwinds. Operating cash flow reached $3.81 billion in 2025, supporting financial stability.
BKR presents a favorable risk-reward profile with 66.7% analyst buy ratings and a $73.25 consensus target offering 14% upside. Key risks include integration challenges from acquisitions and oil market volatility, but strong backlog and margin expansion support the bullish case. The stock remains attractive for investors seeking energy technology exposure with solid cash flow generation.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
